× Information on this section of ECOLEX comes from the InforMEA Portal which compiled information from MEA Secretariats with the support of the European Union. The accuracy of the information displayed is the responsibility of the originating data source. In case of discrepancy the information as displayed on the respective MEA website prevails. Trade in medicinal and aromatic plant species Document type Decision Reference number 19.261 Date Nov 25, 2022 SourceUNEP, InforMEA Status Active Subject Wild species & ecosystems Treaty Convention on International Trade in Endangered Species of Wild Fauna and Flora (Mar 3, 1973) Meeting Nineteenth meeting of the Conference of the Parties Website cites.org Abstract Decision directed to SecretariatThe Secretariat shall, in close collaboration with the Plants Committee: a) publish a notification inviting Parties to: i) share information materials that have been developed to enhance awareness of CITES regulations and to encourage sustainable use and legal trade in CITES-listed medicinal and aromatic plants and, as far as possible, liaise with key stakeholders of medicinal and aromatic plant trade supply chains for this purpose, ii) review their non-detriment findings (NDFs) for medicinal and aromatic plants and consider sharing such with the Secretariat to be included on the NDF section of the CITES website; iii) assess the utility of the Medicinal Plant Names Service (MPNS) database in their routine work to see if it can contribute to the expansion of the Species+ database; and share any experience of using the MPNS database; b) make information materials for raising awareness of CITES regulations for the medicinal and aromatic plant industry stakeholders and consumers available to Parties on the CITES website; c) subject to external funding, undertake an analysis of e-commerce supply chains in products of CITES-listed medicinal and aromatic plant species, exploring the applicability of using the Medicinal Plant Names Service (MPNS) database in the analysis, and including i) a stakeholder analysis of key producers, intermediate traders, manufacturers or distribution platforms to end consumers, and of institutions influencing the demand for CITES-regulated medicinal and aromatic plant products in biomedical, traditional and alternative medical systems, cosmetic and personal care, food industries (as appropriate), and ii) an assessment whether existing annotations are adequate with respect to the principles and principles recommended in Resolution Conf. 11.21 (Rev. CoP19) on Use of annotations in Appendices I and II; and d) report to the Plants Committee on the implementation of this Decision, including suggestions, as appropriate, regarding Resolution Conf. 10.19 (Rev. CoP14) on Traditional medicines or a new Resolution in relation to medicinal and aromatic plant products.